Outlook Therapeutics, Inc. OTLK 深 滬
已收盤 05-08 16:00:00 美东时间
0.2213
+0.006
+2.60%
華盛通- 最 高0.2275
- 今 開0.22
- 成交量 323.38万股
- 最 低 0.22
- 昨 收 0.2157
- 總市值 2672.05万
- 52周最高 3.39
- 市盈率 靜 --
- 換手率 2.68%
- 52周最低 0.1611
- 委 比 94.84%
- 總股本 1.21亿
- 歷史最高 219.20
- 量 比 0.58
- 振 幅 3.48%
- 歷史最低 0.1611
- 每 手 1
- 風險率 0.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Outlook Therapeutics Announces New Equity Financing Transaction
Outlook Therapeutics ( ($OTLK) ) has issued an update. On April 22, 2026, Outlo...
04-24 05:54
Outlook Therapeutics announces $5M registered direct offering priced at-the-market
Outlook Therapeutics (OTLK) on Wednesday said it has entered into an agreement for the purchase and sale of an aggregate of 16.12M shares of its common stock at an offering price of $0.31 per share of...
04-22 20:48
Outlook Therapeutics Completes Federal Dispute Resolution Meeting With The Office Of New Drugs At FDA For Regulatory Nod For ONS-5010 / LYTENAVA
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has completed its Federal
04-21 21:15
Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug
Outlook Therapeutics files FDA dispute on ONS-5010 after CRL citing effectiveness concerns; meeting with agency official set for April 2026.
04-08 02:11
Outlook Therapeutics stock slides after pricing $5M offering
Outlook Therapeutics (OTLK) shares fell 34% in premarket trading Tuesday after the company priced a public offering. The biopharma firm is selling 20M shares along with warrants to buy up to 20M share...
03-24 19:11
Why Paranovus Entertainment Technology Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket
PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global Partners and other stocks moved.
03-24 17:31
Outlook Therapeutics launches public offering; shares down
Outlook Therapeutics (OTLK) has initiated a best-efforts public offering of common stock and accompanying warrants. The offering may include pre-funded warrants in place of common stock. The offering ...
03-24 05:41
Outlook Therapeutics Reveals Proposed Public Offering; No Size Disclosed
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced a best-efforts
03-24 05:35
Outlook Therapeutics Announces Proposed Public Offering
Outlook Therapeutics, Inc. announced the launch of a public offering of its common stock and warrants, with proceeds intended for working capital and general corporate purposes. H.C. Wainwright & Co. serves as the exclusive placement agent. The offering is under a shelf registration statement, and a prospectus supplement will be filed with the SEC. The company, focused on enhancing care for retina diseases, aims to commercialize its ophthalmic be...
03-23 21:30
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
